|
Orthologous residues
|
|
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
ovarian cancer
|
|
Relevant cell lines - cell types - tissues:
OVCAR10 (ovarian), OVCAR5 (ovarian)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
dasatinib
|
|
|
|
decrease
|
|
|
MNLN8237
|
|
|
|
decrease
|
slight decrease
|
|
MNLN8237
|
dasatinib
|
|
|
augment treatment-induced decrease
|
|
|
PHA-680632
|
|
|
|
decrease
|
|
|
PHA-680632
|
dasatinib
|
|
|
augment treatment-induced decrease
|
|
|
nocodazole
|
|
|
|
increase
|
|
|
dasatinib
|
nocodazole
|
|
|
inhibit treatment-induced increase
|
|
|